Bibliographic Details
| Title: |
Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression. |
| Authors: |
Klocker, Eva Valentina1 (AUTHOR), Hasenleithner, Samantha2 (AUTHOR), Bartsch, Rupert3 (AUTHOR), Gampenrieder, Simon P.4 (AUTHOR), Egle, Daniel5 (AUTHOR), Singer, Christian F.6 (AUTHOR), Rinnerthaler, Gabriel1 (AUTHOR), Hubalek, Michael7 (AUTHOR), Schmitz, Katja8,9 (AUTHOR), Bago‐Horvath, Zsuzsanna10 (AUTHOR), Petzer, Andreas11 (AUTHOR), Heibl, Sonja12 (AUTHOR), Heitzer, Ellen13 (AUTHOR), Balic, Marija1,14 (AUTHOR) marija.balic@medunigraz.at, Gnant, Michael15 (AUTHOR) |
| Source: |
Molecular Oncology. Jun2024, p1. 21p. 6 Illustrations, 4 Charts. |
| Abstract: |
The advancements in the detection and characterization of circulating tumor DNA (ctDNA) have revolutionized precision medicine and are likely to transform standard clinical practice. The non‐invasive nature of this approach allows for molecular profiling of the entire tumor entity, while also enabling real‐time monitoring of the effectiveness of cancer therapies as well as the identification of resistance mechanisms to guide targeted therapy. Although the field of ctDNA studies offers a wide range of applications, including in early disease, in this review we mainly focus on the role of ctDNA in the dynamic molecular characterization of unresectable locally advanced and metastatic BC (mBC). Here, we provide clinical practice guidance for the rapidly evolving field of molecular profiling of mBC, outlining the current landscape of liquid biopsy applications and how to choose the right ctDNA assay. Additionally, we underline the importance of exploring the clinical relevance of novel molecular alterations that potentially represent therapeutic targets in mBC, along with mutations where targeted therapy is already approved. Finally, we present a potential roadmap for integrating ctDNA analysis into clinical practice. [ABSTRACT FROM AUTHOR] |
|
Copyright of Molecular Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
